Heparin affects matrix metalloproteinases and tissue inhibitors of metalloproteinases circulating in peripheral blood

Clinical Biochemistry

Volumn 41, Issue 18, 2008, Pages 1466-1473

  Mannello, Ferdinando ^a   Jung, Klaus ^b,c   Tonti, Gaetana A ^a   Canestrari, Franco ^a  

^a UNIVERSITY OF URBINO   (Italy)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Berlin Institute for Urologic Research   (Germany)

Author keywords

Heparin; Matrix metalloproteinases; Peripheral blood; Plasma; Preanalytical pitfalls; Serum; Tissue inhibitors of metalloproteinases

Indexed keywords

ENZYME PRECURSOR; GELATIN; GELATINASE A; GELATINASE B; HEPARIN; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ARTICLE; BLOOD SAMPLING; COMPLEX FORMATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; ZYMOGRAPHY;

ADULT; BLOOD; BLOOD SPECIMEN COLLECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPARIN; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 55949084239     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2008.09.104     Document Type: Article

References (46)

1. McCawley L.J., and Matrisian L.M. Matrix metalloproteinases: they're not just for matrix anymore!. Curr. Opin. Cell Biol. 13 (2001) 534-540
2. Malemud C.J. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci. 11 (2006) 1696-1701
3. Mannello F., Luchetti F., Falcieri E., and Papa S. Multiple roles of matrix metalloproteinases during apoptosis. Apoptosis 10 (2005) 19-24
4. Mannello F., and Gazzanelli G. Tissue inhibitors of metalloproteinases and programmed cell death: conundrums, controversies, and potential implications. Apoptosis 6 (2001) 479-482
5. Mannello F., Tonti G.A., and Papa S. Matrix metalloproteinase inhibitors as anti-cancer therapeutics. Curr. Cancer Drug Targets 5 (2005) 285-298
6. Mannello F. Natural bio-drugs as matrix metalloproteinase inhibitors: new perspectives on the horizon?. Recent Patents Anticancer Drug Discov. 1 (2006) 91-103
7. Moutsiakis D., Mancuso P., Krutzsch H., Stetler-Stevenson W., and Zucker S. Characterization of metalloproteinases and tissue inhibitors of metalloproteinases in human plasma. Connect Tissue Res. 28 (1992) 213-230
8. Zucker S., Hymowitz M., Conner C., et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann. NY. Acad. Sci. 878 (1999) 212-227
9. Zucker S., Doshi K., and Cao J. Measurement of matrix metalloproteinases (MMPs) and Tissue inhibitor of metalloproteinases (TIMPs) in blood and urine: potential clinical application. Adv. Clin. Chem. 38 (2004) 37-85
10. Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 87 (2005) 287-297
11. Fu X., Parks W.C., and Heinecke J.W. Activation and silencing of matrix metalloproteinases. Semin. Cell Dev. Biol. 19 (2008) 2-13
12. Mannello F., and Tonti G.A. Gelatinase concentrations and zymographic profiles in human breast cancer: matrix metalloproteinases circulating in plasma are better markers for the subclassification and early prediction of cancer: the coagulation/fibrinolysis pathways alter the release, activation and recovery of different gelatinases in serum. Int. J. Cancer 121 (2007) 216-218
13. Mannello F. Serum or plasma samples? The "Cinderella" role of blood collection procedures. Preanalytical methodological issues influence the release and activity of circulating matrix metalloproteinases and their tissue inhibitors, hampering diagnostic trueness and leading to misinterpretation. Arterioscler. Thromb. Vasc. Biol. 28 (2008) 611-614
14. Jung K., Nowak L., Lein M., Henke W., Schnorr D., and Loening S.A. Role of specimen collection in preanalytical variation of metalloproteinases and their inhibitors in blood. Clin. Chem. 42 (1996) 2043-2045
15. Lein M., Nowak L., Jung K., et al. Analytical aspects regarding the measurements of metalloproteinases and their inhibitors in blood. Clin. Biochem. 30 (1997) 491-496
16. Jung K., Laube C., Lein M., et al. Kind of sample as preanalytical determinant of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. Clin. Chem. 44 (1998) 1060-1062
17. Jung K., Lein M., Laube C., and Lichtinghagen R. Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood. Clin. Chim. Acta 314 (2001) 241-244
18. Jung K., and Lichtinghagen R. Circulating gelatinase B (MMP-9) - the impact of preanalytical step of blood collection. Matrix Biol. 21 (2002) 381-382
19. Mannello F. Effects of blood collection methods on gelatin zymography of matrix metalloproteinases. Clin. Chem. 49 (2003) 339-340
20. Mannello F., Luchetti F., Canonico B., and Papa S. Effects of anticoagulants and cell separation media as preanalytical determinants on zymographic analysis of plasma matrix metalloproteinases. Clin. Chem. 49 (2003) 1956-1957
21. Jung K., Meisser A., and Bischof P. Blood sampling as critical preanalytical determinant to use circulating MMP and TIMP as surrogate markers for pathological processes. Int. J. Cancer 116 (2005) 1000-1001
22. Meisser A., Cohen M., and Bischof P. Concentrations of circulating gelatinases (Matrix metalloproteinase-2 and -9) are dependent on the conditions of blood collection. Clin. Chem. 51 (2005) 274-276
23. Gerlach R.F., Uzuelli J.A., Souza-Tarla C.D., and Tanus-Santos J.E. Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal. Biochem. 344 (2005) 147-149
24. Souza-Tarla C.D., Uzuelli J.A., Machado A.A., Gerlach R.F., and Tanus-Santos J.E. Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Clin. Biochem. 38 (2005) 410-414
25. Thrailkill K., Cockrell G., Simpson P., Moreau C., Fowlkes J., and Bunn R.C. Physiological matrix metalloproteinase (MMP) concentrations: comparison of serum and plasma specimens. Clin. Chem. Lab. Med. 44 (2006) 503-504
26. Jung K. Sample processing and its preanalytical impact on the measurement of circulating matrix metalloproteinases. Clin. Chem. Lab. Med. 44 (2006) 501-502
27. Jung K., Gerlach R.F., and Tanus-Santos J.E. Preanalytical pitfalls of blood sampling to measure true circulating matrix metalloproteinase 9 and tissue inhibitors of matrix metalloproteinases. Clin. Chim. Acta 373 (2006) 180-181
28. Gerlach R.F., Demacq C., Jung K., and Tanus-Santos J.E. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin. Biochem. 40 (2007) 119-123
29. Castellazzi M., Tamburino C., Fainardi E., et al. Effects of anticoagulants on the activity of the gelatinases. Clin. Biochem. 40 (2007) 1272-1276
30. Rossignol P., Cambillau M., Bissery A., et al. Influence of blood sampling procedure on plasma concentrations of matrix metalloproteinases and their tissue inhibitors. Clin. Exp. Pharmacol. Physiol. 35 (2008) 464-469
31. Jung K., Klotzek S., Stephan C., Mannello F., and Lein M. Impact of blood sampling on the circulating matrix metalloproteinases 1, 2, 3, 7, 8, and 9. Clin. Chem. 54 (2008) 772-774
32. Kilcoyne M., and Joshi L. Carbohydrates in therapeutics. Cardiovasc. Hemathol. Agents Med. Chem. 5 (2007) 186-197
33. Mousa S.A. Heparin, low-molecular weight heparin and derivatives in thrombosis, angiogenesis and inflammation: emerging links. Semin. Thromb. Hemost. 33 (2007) 524-533
34. Sarstedt S-Monovette® tubes, Material safety data sheet on http://www.sarstedt.com (last access 28 April 2008).
35. Johansson S., and Smedsrod B. Identification of a plasma gelatinase in preparations of fibronectin. J. Biol. Chem. 26 (1986) 4363-4366
36. Vartio T., and Baumann M. Human gelatinase/type IV procollagenase is a regular plasma component. FEBS Lett. 255 (1989) 285-289
37. Opdenakker G., Van den Steen P.E., Dubois B., et al. Gelatinase B functions as regulator and effector in leukocyte biology. J. Leuk. Biol. 69 (2001) 851-859
38. Santos-Martinez M.J., Medina C., Jurasz P., and Radomski M.W. Role of metalloproteinases in platelet function. Thromb. Res. 121 (2008) 535-542
39. Kodama S., Iwata K., Iwata H., Yamashita K., and Hayakawa T. Rapid one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases: an application for rheumatoid arthritis in serum and plasma. J. Immunol. Methdos 127 (1990) 103-108
40. Fernandez-Patron C., Martinez-Cuesta M.A., Salas E., et al. Differential regulation of platelet aggregation by matrix metalloproteinase-9 and -2. Thromb. Haemost. 82 (1999) 1730-1735
41. Murate T., and Hayakawa T. Multiple functions of tissue inhibitors of metalloproteinases (TIMPs): new aspects in hematopoiesis. Platelets 10 (1999) 5-16
42. Mollinedo F., Nakajima M., Llorens A., et al. Major co-localization of the extracellular-matrix degradative enzymes heparanase and gelatinase in tertiary granules of human neutrophils. Biochem. J. 327 (1997) 917-923
43. Makowski G.S., and Ramsby M.L. Use of citrate to minimize neutrophil matrix metalloproteinase-9 in human plasma. Anal. Biochem. 322 (2003) 283-286
44. Walenga J.M. Non-anticoagulant effects of unfractionated and low-molecular weight heparins. Clin. Adv. Hematol. Oncol. 5 (2007) 759-760
45. Mannello F., and Sebastiani M. Zymographic analyses and measurement of matrix metalloproteinase-2 and -9 in nipple aspirate fluids. Clin. Chem. 49 (2003) 1546-1550
46. Van Wart H.E., and Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 5578-5582